XL-PROTEIN
LIVE

Serial Number

79139380

Owner

XL-protein GmbH

Attorney

Anthony G. Craig

Filing Date

Apr 26, 2013

Add to watchlist:

No watchlists yet
View on USPTO

XL-PROTEIN Trademark

Serial Number: 79139380 • Registration: 4634784

XL-PROTEIN is a trademark filed by XL-protein GmbH on April 26, 2013. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

XL-protein GmbH (5 trademarks)

Lise-Meitner-Str. 30
Freising 85354 , DE

Entity Type: 03

Trademark Details

Filing Date

April 26, 2013

Registration Date

November 11, 2014

Published for Opposition

August 26, 2014

Cancellation Date

April 26, 2023

Goods & Services

[ Pharmaceutical and veterinary preparations, preparations for human medical purposes for use in treating growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, bone diseases; ] sanitary preparations for medical purposes; [ dietetic substances adapted for medical use, namely, nutritional supplements containing proteins, peptides, food for babies; ] preparations for destroying vermin; fungicides, herbicides [ ; pharmaceutical and diagnostic preparations for medical, dental and forensic purposes and for purposes of forensic medicine and laboratory medicine, namely, pharmaceutical and diagnostic preparations for diagnosis, prevention, treatment or cure of growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, bone diseases; testing reagents in kit form for medical, dental and forensic purposes and for purposes of forensic medicine and laboratory medicine, namely, medical and forensic diagnostic reagents and assays for testing of body tissues and body fluids; chemical and biotechnological preparations for medical and diagnostic purposes, namely, reagents and solvents for sample preparation, modification and manipulation of cells and for performing of marking, separation, isolation, purification, amplification and/or analytical methods for biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances for diagnostic purposes included in this class; medicaments for preventive, curative and palliative purposes for preventing, treating or curing of growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, bone diseases; medical biomarkers, in particular for preventative, diagnostic, prognostic or predictive purposes, namely, polypeptide sequences; medical preparations, namely, kits for laboratory medicine in particular for preventive, diagnostic, prognostic or predictive purposes, namely, diagnostic kits consisting primarily of proteins, buffers, and reagents for use in detecting growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, bone diseases; biomolecules (targets) for medical purposes, namely, proteins, peptides and small molecule drugs with conjugated polypeptide sequences for binding of active substances; medical preparations for analytical purposes, namely, reagents for detecting growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, bone diseases; preparations for health care, namely, for diagnosis, prevention, treatment, or cure of growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, bone diseases ]

[ Chemical and biochemical preparations for use in research and laboratories, except for medical and veterinary use, as well as for industrial and scientific use; ] unprocessed artificial resins, unprocessed plastics

[ Scientific and technological services and research, namely, scientific research, analysis, testing, in the field of chemistry, genetics, biology, biotechnology and biochemistry; technical services, namely, computer diagnostic services in the field of DNA, RNA and protein expression, detection and analysis and respective design services, in particular in the field of chemistry, genetics, biology, biotechnology and biochemistry; industrial analysis and research services in the field of medical, dental, forensic and scientific research; ] design and development of computer hardware [ and software; services of a chemical and biochemical laboratory; scientific research including conducting of scientific examinations and preparation of scientific opinions; quality checking, namely, quality evaluation services for the medical and pharmaceutical industry; design and development of programs for data processing; consultancy for scientific, laboratory and research purposes in the field of chemistry, genetics, biology, biotechnology and biochemistry; scientific services of a technical measuring and test laboratory; technological consulting services pertaining to scientific and industrial scientific research in the fields of generation, technical processing and technical analysis of biomaterials and medically relevant data ]

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Nov 20, 2023 DENC
DEATH OF INTERNATIONAL REGISTRATION
Nov 20, 2023 DETH
TOTAL INVALIDATION PROCESSED BY THE IB
Jul 17, 2022 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
May 20, 2022 INTS
INVALIDATION PROCESSED
May 20, 2022 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Jan 28, 2022 INTR
CANCELLED SECTION 71
May 28, 2021 C71T
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
Sep 23, 2020 INNA
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Sep 23, 2020 INPR
LIMITATION FROM THE IB EXAMINED AND ENTERED
Jan 14, 2020 LIME
CORRECTION UNDER SECTION 7 - PROCESSED
Jan 13, 2020 COC.
ASSIGNED TO PARALEGAL
Jan 13, 2020 PLGL
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Nov 11, 2019 REM3
LIMITATION OF GOODS RECEIVED FROM IB
Aug 9, 2019 LIMG
NEW REPRESENTATIVE AT IB RECEIVED
Jul 13, 2017 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 24, 2015 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 2, 2015 FICS
FINAL DISPOSITION PROCESSED
Apr 2, 2015 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 11, 2015 FICR
REGISTERED-PRINCIPAL REGISTER
Nov 11, 2014 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 26, 2014 NPUB
PUBLISHED FOR OPPOSITION
Aug 26, 2014 PUBO
NOTIFICATION PROCESSED BY IB
Aug 22, 2014 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 6, 2014 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Aug 6, 2014 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 6, 2014 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jul 18, 2014 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 18, 2014 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 26, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 26, 2014 CRFA
ASSIGNED TO LIE
Jun 16, 2014 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 4, 2014 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 4, 2014 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 4, 2014 REAP
REFUSAL PROCESSED BY IB
Dec 31, 2013 RFNT
APPLICATION FILING RECEIPT MAILED
Dec 13, 2013 MAFR
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 10, 2013 RFCS
REFUSAL PROCESSED BY MPU
Dec 10, 2013 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 10, 2013 RFCR
NON-FINAL ACTION WRITTEN
Dec 9, 2013 CNRT
ASSIGNED TO EXAMINER
Dec 9, 2013 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 9, 2013 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 6, 2013 REPR